JP2022058371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022058371A5 JP2022058371A5 JP2021205061A JP2021205061A JP2022058371A5 JP 2022058371 A5 JP2022058371 A5 JP 2022058371A5 JP 2021205061 A JP2021205061 A JP 2021205061A JP 2021205061 A JP2021205061 A JP 2021205061A JP 2022058371 A5 JP2022058371 A5 JP 2022058371A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cancer
- heterocyclyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 19
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 150000005347 biaryls Chemical group 0.000 claims description 15
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 14
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 150000005363 heterobiaryls Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 201000001256 adenosarcoma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000004252 chorionic villi Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 208000013706 tumor of meninges Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 2
- -1 -NR 15 R 16 Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212520P | 2015-08-31 | 2015-08-31 | |
| US62/212,520 | 2015-08-31 | ||
| JP2018507636A JP2018528189A (ja) | 2015-08-31 | 2016-08-31 | ヘテロアリール化合物および治療薬としてのそれらの使用 |
| PCT/KR2016/009743 WO2017039331A1 (en) | 2015-08-31 | 2016-08-31 | Heteroaryl compounds and their use as therapeutic drugs |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507636A Division JP2018528189A (ja) | 2015-08-31 | 2016-08-31 | ヘテロアリール化合物および治療薬としてのそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022058371A JP2022058371A (ja) | 2022-04-12 |
| JP2022058371A5 true JP2022058371A5 (enExample) | 2022-07-04 |
| JP7208348B2 JP7208348B2 (ja) | 2023-01-18 |
Family
ID=58188774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507636A Pending JP2018528189A (ja) | 2015-08-31 | 2016-08-31 | ヘテロアリール化合物および治療薬としてのそれらの使用 |
| JP2021205061A Active JP7208348B2 (ja) | 2015-08-31 | 2021-12-17 | ヘテロアリール化合物および治療薬としてのそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507636A Pending JP2018528189A (ja) | 2015-08-31 | 2016-08-31 | ヘテロアリール化合物および治療薬としてのそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10125118B2 (enExample) |
| EP (1) | EP3344613B1 (enExample) |
| JP (2) | JP2018528189A (enExample) |
| KR (1) | KR102663118B1 (enExample) |
| CN (1) | CN108368083B (enExample) |
| AU (1) | AU2016317806B2 (enExample) |
| BR (1) | BR112018004065B1 (enExample) |
| CA (1) | CA2995675C (enExample) |
| CL (1) | CL2018000529A1 (enExample) |
| CO (1) | CO2018002045A2 (enExample) |
| CR (1) | CR20180184A (enExample) |
| ES (1) | ES2799300T3 (enExample) |
| IL (1) | IL257391B (enExample) |
| MX (1) | MX387785B (enExample) |
| MY (1) | MY199607A (enExample) |
| PE (1) | PE20181017A1 (enExample) |
| PH (1) | PH12018500432A1 (enExample) |
| RU (1) | RU2723480C2 (enExample) |
| UA (1) | UA126372C2 (enExample) |
| WO (1) | WO2017039331A1 (enExample) |
| ZA (1) | ZA201802033B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017039331A1 (en) | 2015-08-31 | 2017-03-09 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as therapeutic drugs |
| SI3971177T1 (sl) | 2016-07-20 | 2024-10-30 | Novartis Ag | Derivati aminopiridina in njihova uporaba kot selektivni zaviralci ALK-2 |
| ES2903528T3 (es) | 2016-10-10 | 2022-04-04 | Dong A Socio Holdings Co Ltd | Compuestos de heteroarilo y su uso como inhibidores de MER |
| GB201820458D0 (en) * | 2018-12-14 | 2019-01-30 | Heptares Therapeutics Ltd | Ox1 antagonists |
| GB201901142D0 (en) | 2019-01-28 | 2019-03-20 | Heptares Therapeutics Ltd | OX1 Antagonists |
| GB201905328D0 (en) * | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
| CN115968289B (zh) | 2020-06-16 | 2025-09-30 | 因赛特公司 | 用于治疗贫血的alk2抑制剂 |
| WO2022065962A1 (ko) * | 2020-09-28 | 2022-03-31 | 한국화학연구원 | Mlkl 결합 또는 분해용 화합물 및 이들의 의약 용도 |
| TWI893486B (zh) * | 2022-10-20 | 2025-08-11 | 南韓商東亞Ｓｔ股份有限公司 | 稠合雙環化合物及其等作為mer及axl抑制劑的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| WO2003093297A2 (en) * | 2002-05-03 | 2003-11-13 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US8030336B2 (en) | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
| WO2004054977A1 (en) | 2002-12-13 | 2004-07-01 | Cytopia Pty Ltd | Nicotinamide-based kinase inhibitors |
| MXPA05009245A (es) | 2003-03-11 | 2005-10-19 | Pfizer Prod Inc | Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf). |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| WO2007011760A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| US9408873B2 (en) * | 2010-08-23 | 2016-08-09 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases |
| JP6012735B2 (ja) | 2011-09-15 | 2016-10-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規ジヒドロキノリン−２−オン誘導体 |
| WO2017039331A1 (en) | 2015-08-31 | 2017-03-09 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as therapeutic drugs |
-
2016
- 2016-08-31 WO PCT/KR2016/009743 patent/WO2017039331A1/en not_active Ceased
- 2016-08-31 PE PE2018000308A patent/PE20181017A1/es unknown
- 2016-08-31 ES ES16842297T patent/ES2799300T3/es active Active
- 2016-08-31 RU RU2018111072A patent/RU2723480C2/ru active
- 2016-08-31 EP EP16842297.0A patent/EP3344613B1/en active Active
- 2016-08-31 JP JP2018507636A patent/JP2018528189A/ja active Pending
- 2016-08-31 KR KR1020187008806A patent/KR102663118B1/ko active Active
- 2016-08-31 BR BR112018004065-7A patent/BR112018004065B1/pt active IP Right Grant
- 2016-08-31 CN CN201680062207.9A patent/CN108368083B/zh active Active
- 2016-08-31 UA UAA201803262A patent/UA126372C2/uk unknown
- 2016-08-31 US US15/253,773 patent/US10125118B2/en active Active
- 2016-08-31 MX MX2018002574A patent/MX387785B/es unknown
- 2016-08-31 CA CA2995675A patent/CA2995675C/en active Active
- 2016-08-31 AU AU2016317806A patent/AU2016317806B2/en active Active
- 2016-08-31 MY MYPI2018700596A patent/MY199607A/en unknown
- 2016-08-31 CR CR20180184A patent/CR20180184A/es unknown
-
2018
- 2018-02-07 IL IL257391A patent/IL257391B/en active IP Right Grant
- 2018-02-26 CO CONC2018/0002045A patent/CO2018002045A2/es unknown
- 2018-02-27 PH PH12018500432A patent/PH12018500432A1/en unknown
- 2018-02-27 CL CL2018000529A patent/CL2018000529A1/es unknown
- 2018-03-27 ZA ZA2018/02033A patent/ZA201802033B/en unknown
- 2018-09-25 US US16/141,044 patent/US10947215B2/en active Active
-
2020
- 2020-12-30 US US17/138,309 patent/US12195446B2/en active Active
-
2021
- 2021-12-17 JP JP2021205061A patent/JP7208348B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022058371A5 (enExample) | ||
| JP2017521420A5 (enExample) | ||
| RU2003117476A (ru) | Аминотиазолы и их применение в качестве антагонистов рецептора аденозина | |
| JP7085032B2 (ja) | ナフチリジン化合物、薬物組成物およびそれらの応用 | |
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| JP2017504642A5 (enExample) | ||
| RU2003119153A (ru) | Орто-, мета-замещенные бис-арильные соединения, способ их получения, их применение в качестве медикаментов, а также содержащие их фармацевтические композиции | |
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2019510832A5 (enExample) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| WO2021076890A4 (en) | INHIBITING HUMAN INTEGRIN α4β7 | |
| JP2014513704A5 (enExample) | ||
| JPWO2020260252A5 (enExample) | ||
| RU2006107785A (ru) | 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| JP2008505157A5 (enExample) | ||
| FI4084779T3 (fi) | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia | |
| JP2019501196A5 (ja) | 腫瘍を処置するための抗ｃｄ２０組み合わせ | |
| JP2018504441A5 (enExample) | ||
| KR102708246B1 (ko) | 식도암을 치료하기 위한 퀴놀린 유도체의 용도 및 치료방법, 이의 약제학적 조성물 및 키트 | |
| JP2009534418A5 (enExample) | ||
| JP2005526138A5 (enExample) | ||
| RU2017106260A (ru) | Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата | |
| EA200701780A1 (ru) | Противоопухолевое средство |